+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Bioterrorism and emerging infectious disease - antimicrobials, therapeutics and immune-modulators. SARS coronavirus



Bioterrorism and emerging infectious disease - antimicrobials, therapeutics and immune-modulators. SARS coronavirus



Idrugs 7(2): 91-95



The purpose of this meeting was to provide a forum for expert presentations and discussion about the threats of bioterrorism and emerging infectious diseases, and to address the issues relating to epidemics, prevention of infection and treatment of some of these emerging infectious diseases classified as potential agents of bioterror. Included in the talks were state-of-the-art presentations about infectious clone technology and recombinant viruses, pathogen and receptor interactions at the cellular and molecular level, genomic responses to infection, and new information on antiviral mechanisms of action. Severe acute respiratory syndrome (SARS) and progress toward understanding the epidemic was addressed, and other sessions were presented concerning immune therapy and immunopotentiation of disease, siRNA and gene silencing, host responses to pathogen infections, as well as the use of genetic engineering to circumvent and direct the immune response. Many discussions were held and data were presented about possible compounds and new drugs that may have antiviral properties, yet there were few discussions of any available new drugs. This report addresses reverse genetics of SARS virus, as well as its epidemiology, and a host of different recent approaches to developing antivirals effective against SARS, including some potential vaccine candidates. Also presented are hypotheses about the human immune response to SARS infection, as well as immune therapies against botulinum and anthrax toxins. This report also addresses antiviral approaches exploiting siRNAs, and different aspects of the host immune response to many of the different dangerous pathogens discussed at this meeting. Finally, approaches to circumventing and directing the immune response using genetic engineering will be reported.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 048388800

Download citation: RISBibTeXText

PMID: 15057645


Related references

Bioterrorism and emerging infectious disease - antimicrobials, therapeutics and immune-modulators. Viral infections. Idrugs 7(2): 96-99, 2004

Structural proteomics of the SARS coronavirus: a model response to emerging infectious diseases. Journal of Structural and Functional Genomics 8(2-3): 85-97, 2007

Mouse studies of SARS coronavirus-specific immune responses to recombinant replication-defective adenovirus expressing SARS coronavirus N protein. Hong Kong Medical Journal 15(Suppl. 2): 33-36, 2009

Rapid Response Research - Sars Coronavirus Vaccines and Application of Processes to Other Emerging Infectious Diseases. Current Immunology Reviews 1(2): 185-200, 2005

Differential sensitivities of severe acute respiratory syndrome (SARS) coronavirus spike polypeptide enzyme-linked immunosorbent assay (ELISA) and SARS coronavirus nucleocapsid protein ELISA for serodiagnosis of SARS coronavirus pneumonia. Journal of Clinical Microbiology 43(7): 3054-3058, 2005

Emerging Infections: What Have We Learnt from SARS? || Viral Evolution and the Emergence of SARS Coronavirus. Philosophical Transactions Biological Sciences 359(1447): 1059-1065, 2004

SARS coronavirus infection: pathology and pathogenesis of an emerging virus disease. Coronaviruses with special emphasis on first insights concerning SARS: 87-99, 2005

Emerging Infections: What Have We Learnt from SARS? || Animal Origins of SARS Coronavirus: Possible Links with the International Trade in Small Carnivores. Philosophical Transactions Biological Sciences 359(1447): 1107-1114, 2004

Emerging Infections: What Have We Learnt from SARS? || Influenza as a Model System for Studying the Cross-Species Transfer and Evolution of the SARS Coronavirus. Philosophical Transactions Biological Sciences 359(1447): 1067-1073, 2004

A new infectious disease challenge: Urbani severe acute respiratory syndrome (SARS) associated coronavirus. Immunology 109(3): 326-328, 2003

SARS, emerging infections, and bioterrorism preparedness. Lancet. Infectious Diseases 4(8): 483-484, 2004

Humoral and cellular immune responses induced by 3a DNA vaccines against severe acute respiratory syndrome (SARS) or SARS-like coronavirus in mice. Clinical and Vaccine Immunology 16(1): 73-77, 2009

Homelessness and the response to emerging infectious disease outbreaks: lessons from SARS. Journal of Urban Health 85(3): 402-410, 2008

Homelessness and the response to emerging infectious disease outbreaks lessons from SARS. Journal Of Urban Health: Bulletin Of The New York Academy Of Medicine: 3, 402-410, 2008

Mutagenesis of the transmembrane domain of the SARS coronavirus spike glycoprotein: refinement of the requirements for SARS coronavirus cell entry. Virology Journal 6: 230, 2009